Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 11/20 | 0.38 |
| ▸ | LOX | P28300 | 4/20 | 0.38 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15409505 | 0.87 | KDM4E (0.41) | KDM4EALDH1A1S1PR1 | |
| SCHEMBL28799681 | 0.77 | RECQL (0.52) | LOXL2LOXLOXL3KDM4EALDH1A1 | |
| SCHEMBL17832058 | 0.76 | NOS3 (0.46) | KDM4EALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL20339346 | 0.75 | HSD17B10 (0.43) | KDM4ENOS3NOS1NOS2 | |
| SCHEMBL29370384 | 0.75 | HSD17B10 (0.43) | KDM4ENOS3NOS1NOS2 | |
| SCHEMBL4107151 | 0.75 | LOXL2 (0.61) | LOXL2LOXLOXL3NOS3NOS1 | |
| SCHEMBL18012380 | 0.75 | HDAC3 (0.33) | KDM4EALDH1A1 | |
| SCHEMBL18986772 | 0.74 | PDE4A (0.33) | LOXL2LOXLOXL3 | |
| SCHEMBL21594253 | 0.73 | LOXL2 (0.56) | LOXL2LOX | |
| SCHEMBL22264270 | 0.73 | LOXL2 (0.56) | LOXL2LOXS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871940-B2 | Unsymmetrical bisazides for chemoselective sequential ligation | The Florida State University Research Foundation, Inc. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140018541-A1 | UMSYMMETRICAL BISAZIDES FOR CHEMOSELECTIVE SEQUENTIAL LIGATION | The Florida State University Research Foundation, Inc. (US) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018541-A1 | UMSYMMETRICAL BISAZIDES FOR CHEMOSELECTIVE SEQUENTIAL LIGATION | UTS2R, UMPS, UGP2 | LOXL2 1383/4885LOX 1660/4885LOXL3 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.